Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

171.10 +5.72 (+3.46%)
Streaming Delayed Price Updated: 2:21 PM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
News headline image
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over ↗
Via The Motley Fool
News headline image
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside ↗
UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024. 
Via Benzinga
News headline image
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 ↗
Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show gradual growth amid market challenges. 
Via Benzinga
News headline image
This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Biogen Through Analyst Insights ↗
 
Via Benzinga
News headline image
Evaluating Biogen: Insights From 17 Financial Analysts ↗
 
Via Benzinga
News headline image
Biogen Analysts Slash Their Forecasts After Q3 Results ↗
 
Via Benzinga
News headline image
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
News headline image
This Kraft Heinz Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
News headline image
Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum ↗
The biotech giant also raised full-year EPS guidance. 
Via Investor's Business Daily
News headline image
Looking Into Biogen's Recent Short Interest ↗
 
Via Benzinga
News headline image
Biogen (BIIB) Q3 2024 Earnings Call Transcript ↗
BIIB earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook ↗
Biogen's Q2 revenue fell 3% to $2.47 billion exceeding estimates, with adjusted EPS of $4.08. Multiple sclerosis sales dipped, while new products buoyed performance. 
Via Benzinga
News headline image
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock ↗
Fewer contenders means fewer constraints on expanding market share. 
Via The Motley Fool
News headline image
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce ↗
Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and... 
Via Benzinga
Topics Workforce
News headline image
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock ↗
Oppenheimer has initiated coverage on Larimar Therapeutics, emphasizing its lead program Nomlabofusp as a transformative therapy for Friedreich's ataxia. With a price target of $26, the company plans... 
Via Benzinga
News headline image
The Latest Analyst Ratings For Biogen ↗
 
Via Benzinga
News headline image
Looking Into Biogen's Recent Short Interest ↗
 
Via Benzinga
News headline image
Forecasting The Future: 20 Analyst Projections For Biogen ↗
 
Via Benzinga
News headline image
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe ↗
Eli Lilly invests £279M in the UK to boost life sciences, while its Alzheimer's drug, donanemab, faces European regulatory hurdles amid ongoing trials and safety concerns. 
Via Benzinga
News headline image
Large-Cap Stocks In Trouble - Sunday, Oct. 13 ↗
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
News headline image
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study ↗
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%. 
Via Benzinga
News headline image
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year ↗
Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared... 
Via Benzinga
News headline image
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030 ↗
It's hard to bet against this company right now. 
Via The Motley Fool
News headline image
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate ↗
Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by February... 
Via Benzinga
News headline image
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial ↗
UCB and Biogen announced positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus, showing significant improvement in disease activity after 48... 
Via Benzinga
News headline image
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know ↗
Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately. 
Via Benzinga
News headline image
Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?' ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.